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Resumo 
 
 
A deficiência em 3-hidroxiacil-CoA desidrogenase de ácidos gordos de cadeia 
longa (LCHAD) é uma desordem da oxidação lipídica mitocondrial que apesar 
de rara está associada a um mau prognóstico devido às suas graves 
consequências clínicas. Apesar de a implementação dos programas de 
rastreio neonatal em alguns países desenvolvidos, incluindo Portugal, ter 
contribuído para uma melhor compreensão das doenças metabólicas e para a 
prevenção das suas consequências, os mecanismos fisiopatológicos 
subjacentes à LCHAD ainda são pouco compreendidos.  
No sentido de contribuir para a elucidação destes mecanismos, avaliou-se a 
plasticidade mitocondrial em resposta à deficiência em LCHAD. Assim, foram 
isoladas mitocôndrias de culturas de fibroblastos obtidas a partir de biópsias de 
pele de doentes com deficiência em LCHAD e o seu proteoma foi 
caracterizado e comparado com amostras obtidas de indivíduos saudáveis. 
Recorrendo a nanoLC-MS/MS 729 proteínas distintas foram identificadas, a 
grande maioria pertencente aos seguintes clusters funcionais “metabolismo”, 
“transporte”, “transdução de sinal”, “processos de desenvolvimento e geração 
de percursores de metabolitos e energia”. Da análise dos resultados obtidos 
com marcação com iTRAQs identificaram-se 40 proteínas diferentemente 
expressas entre os dois doentes com défice de LCHAD e os controlos entre 
elas estão chaperones, protéases, proteínas associadas ao metabolismo e 
ainda proteínas associadas ao stress oxidativo.  
Em geral, este estudo permitiu a obtenção de uma perspetiva global da 
plasticidade do proteoma mitocondrial perante a deficiência em LCHAD e 
evidenciou as vias moleculares envolvidas na sua patogénese. 
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abstract 
 
Bladder cancer is one of the most common cancers in humans and its 
incidence has been increasing during the past years. Seventy percent of newly 
diagnosed bladder cancers are classified as non-muscle-invasive bladder 
cancer (NMIBC) and are often associated with high rates of recurrence that 
require lifelong surveillance. Bacillus Calmette-Guérin (BCG) immunotherapy is 
the treatment of choice of this disease. However, at the moment there are no 
biomarkers to predict BCG therapeutics outcome. 
It is now recognized that malignant transformations are often accompanied by a 
dysregulation at the O-glycosylation level with an overexpression of short chair 
O-glycans. Still, little is known regarding their expression in bladder tumors.  
Taking into account these considerations, this work begins by characterizing 
(Tn, STn, T, ST, S6T and S3T) antigens in 29 bladder tumors with different 
clinicopathological natures, low grade (n=17) and high grade (n=7) NMIBC and 
MIBC (n=5) by immunohistochemistry. This study has demonstrated that 
sialylated species predominate over neutral antigens (Tn and T). S6T had 
broader expression (approximately 90% of the tumors) being prevalent among 
low grade cases. In contrast, S3T expression was more restricted (48%) and 
more associated with high-grade. It was also observed that STn is 
characteristic of high grade and invasive tumors (71 and 80% respectively) that 
currently constitute the primary concern in bladder cancer management. In this 
context, it was determined the predictive value of STn in BCG immunotherapy 
outcome in a retrospective series of 94 high-risk tumors. This showed that 
positivity for this antigen was associated with a better response to treatment (p 
= 0.024). Moreover it Highlighted the trend towards an increased survival. The 
incorporation of the antigen S6T, which has the STn domain, into this model 
increased the overall response (p = 0.001) and survival (p = 0.001). Thus, 
important information was collected that may guide future studies in the 
understanding of tumor behaviour, definition of high-risk populations and 
therapeutics.  
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Abbreviations  
 
β4/3GalTs  β1,-4/3 Galactosyltranferases 
β3/4GnTs  β1-3/4 N-acetylglucosaminyltransferases 
BC   Bladder Cancer 
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1. General Introduction 
 
Bladder cancer (BC) is one of the fifth most common human malignancy 
worldwide and its incidence has been increasing in recent years [1-3]. Moreover, it’s the 
second most common urological tumor, particularly after the fifth decade of life and 
mostly in males [4-6]. 
The BC includes different histopathological entities, the majority being urothelial 
carcinoma. Urothelial cell carcinoma or UCC is a heterogeneous disease in respect of its 
natural and prognostic histology and is observed in more than 90% of tumors [4, 7]. At 
diagnosis, more than 75% of UCC cases are superficial non-muscle invasive cancers 
(NMIBC) [2, 8]. These include carcinomas limited to the mucosa, such as carcinoma in 
situ (CIS) and non-invasive papillary carcinoma (pTa), and tumors of the stage T1 
extending from the urothelium and penetrating the basement membrane to the lamina 
propria [2]. Patients with NMIBC have a 5-years survival rate of between 88-98% [9]. In 
opposite, the 5-year survival rate for patients presenting muscle invasive disease (MIBC, 
pT2-pT4) is 46-63%, and falls to only 15% in those with locally advanced and metastatic 
disease (Figure 1) [3, 10-12]. According to current guidelines [2] these tumors are often 
divided into low grade tumors (mostly Ta) and high grade tumors (Ta and T1) that exhibit 
poorly differentiated cells.  
Even though most cases are superficial NMIBC, BC presents the highest recurrence 
rate among solid tumors [12, 13]. Moreover, approximately 30-40% presents an elevated 
risk of progression to muscle invasive disease correlated with poor prognosis [5, 14]. 
Presently, the risk of relapse and progression is based exclusively with several clinical and 
histopathological factors (number and size of tumors, number of previous relapses, local 
staging (T) degree of differentiation and CIS presence) combined on a scoring system 
defined by the European Organization for Research and Treatment of Cancer (EORTC)  [4, 
12]. This group comprehends low grade tumors with persistent recurrence, multifocal 
disease, carcinoma in situ (CIS) and high-grade papillary tumors. Yet, due to the 
heterogeneous biological behaviour of tumors and the inter/intra-observer variability the 
accuracy of these models is as high as 70% [15, 16]. As such, during the last two decades, 
large number molecular markers have been associated with high-risk disease. However, 
and despite promising results, no single marker is able to predict with accuracy tumor 
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behavior [16]. It is now consensual that the integration of multiple biomarkers can improve 
the predictive value of this model; still such a panel remains to be established. 
 
 
Figure 1: Illustration of the extent of tumor invasion in Bladder Cancer (Adapted from [3]). 
 
Therapeutics based on the transurethral resection of the bladder tumor (TURBT) is 
usually enough for low-risk cases [17, 18]. However, to reduce recurrence rates and 
present disease progression, TURBT may be followed by an immediate postoperative 
instillation of chemotherapy, and/or an adjuvant course of intravesical chemotherapy or 
immunotherapy with Bacillus Calmette-Guérin; (BCG) [19-21]. Several studies have 
described that the BCG immunotherapy mechanism of action involves adhesion and 
internalization by cells, followed by tumor cell apoptosis and host adaptative immune 
response [10, 19, 20, 22]. Until now, intravesical BCG instillations have proven to be the 
most successful adjuvant treatment for patients with intermediate and high-risk NMIBC [2, 
23, 24]. Still, 30–50% of patients fail to respond treatment and 15% have progression to 
muscle-invasive disease [13, 20]. Additionally, as there are no established markers to assist 
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prognostication, therapeutic failure is currently defined base either on recurrence or 
intolerance to BCG. The risk stratification is imperative for classifying patients with 
similar risks of recurrence and progression, and it helps to determine the appropriate 
management strategies for each risk category. Thus, the establishment of a biomarker panel 
to predict tumor behaviour, guiding the decision-making process between conservative 
treatment and radical approaches like cystectomy, is necessary. This is one of the most 
critical topics in high risk NMIBC management. 
It is now recognized that, malignant transformation is often accompanied by a 
deregulation at the O-glycosylation level with an overexpression of short chair O-glycans. 
[25-27].  In particular, the expression of sialylated simple mucin type O-GalNAc glycans, 
have profound biological implications by influencing cell-cell interactions and cell-
extracellular matrix, which consequently will interfere with tumor progression, metastasis, 
immune response, host-pathogen interaction and response to therapy [25]. These antigens 
are generally absent in healthy tissues and have been identified in different tumor types, 
including bladder cancers [28, 29]. Also, recent in vitro studies have demonstrated that 
cells over-expressing tumor-associated form STn presented higher levels of adhesion and 
internalization of the bacillus [97]. These observations are in agreement with other reports 
that BCG can bind human cell-surface glycans [19, 20]. According to all this information, 
alterations in O-glycosylation patterns, may determine the BCG therapeutics result, and so 
be explored as biomarkers. Yet, little is known about the pattern of expression of simple 
mucin type O-GalNAc glycans in bladder tumors. 
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2. O-Glycosylation in human cells 
Glycosylation is one of the most ubiquitous and complex post-translational 
modification (PTM) and is estimated to occur on more than half of the proteins encoded in 
eukaryotic human genomes [31]. O-glycosylation is among the most common and is 
frequently associated with mucins due to the high density of putative glycosylation sites 
encountered in this class of proteins. However, O-glycans can be found in many other 
proteins.  The O-glycosylation of proteins is generally initiated by the transfer of a N-
acetyl-galactosamine (GalNAc) from UDP-GalNAc to hydroxyl groups in serine (Ser) or 
treonine (Thr) (Figure 2) [25, 32]. This is catalysed by a large family of proteins, termed 
polypeptide N-acetyl-galactosaminyltransferases GalNAc-transferases (ppGalNAc-Ts), in 
the Golgi complex, and results in the formation of the Tn antigen (GalNAcα-O-Ser/Thr) 
[33-36].  
There are up to 20 different known isoforms of ppGalNAc-Ts which are 
differentially expressed according to the tissue [37, 38]. Moreover, they show different 
site-dependent specificities and act in a concerted and highly regulated manner, to 
determine the density and O-glycosylation of these sites [34]. After the formation of Tn 
antigen, increased levels of α2-6 sialyltransferases ST6GalNAc-I/II promote the sialylation 
of the respective epitope originating the sialyl-Tn antigen (Neu5Acα2-6GalNAcα-O-
Ser/Thr) thus, prematurely ending chain extension. Yet, the elongation of the Tn antigen is 
the most common event in non-pathological conditions, [26, 27]. The second step towards 
elongation involves the transfer of galactose (Gal) Tn antigen, resulting in the T antigen or 
core 1 (Galβ1-3GalNAcα-O-Ser/Thr) formation [39]. This reaction is catalysed by core 1 
β1-3N-galactosiltransferase (T sintase or C1GalT-1) [40]. On the other hand, depending on 
the tissue, the action of the core 3 β1-3N-acetylglucosaminiltransferase (C3GnT) on Tn 
antigen, may lead to the formation of core 3 (GlcNAcβ1-3GalNAcα-O-Ser/Thr) that is 
often a precursor of more complex structures. Namely, core 3 can be elongate by the core 
2/4 β1N-acetilglucosaminiltransferase (C2GnT-2), resulting in the core 4 that can then 
result in oligomeric structures. However, the T antigen can also be sialylated by α2-3 
ST3Gal-I/II/IV or α2-6 ST6GalNAc-II/III/IV stopping elongation [26]. ST3Gal-I,II and IV 
are known to promote the sialylation of the O-3 position of the Gal residue originating the 
S3T antigen (Neu5Acα2-3Galβ1-3GalNAcα-O-Ser/Thr). The α2-6 ST6GalNAc-II/III and 
IV promote the sialylation of the O-6 position of the GalNAc residue originating the STn-
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like glycan, S6T (Galβ1-3(Neu5Acα2-6) GalNAcα-O-Ser/Thr). The concerted action of 
both enzymes originates the di-sialylated T antigen (DST) [25-27, 32]. Since the Tn and T 
antigens and their sialylated counterparts have been classically found in mucins they have 
been termed simple mucin-type O-GalNAc glycans. In addition, the mono-sialylated T 
antigens (S3T and S6T) are generally termed by some authors as sialyl T or cryptic T 
antigens (ST). Adding some confusion to this nomenclature, some authors using 
immunological approaches have also include the DST antigens as part of ST antigens. This 
resulted from the lack of monoclonal antibodies to each specific form of ST as ledding to 
their assessment using an anti-T antibody after treatment with a -neuraminidase [41]. 
Still, the elongation of the T antigen normally prevails over this sialylated 
structures, by the action of the β1-6 N-acetilglucosaminiltransferase (C2GnT-1/3), 
originating the core 2 (GlcNAcβ1-6(Galβ1-3)GalNAcα-O-Ser/Thr). The elongation of core 
structures results from the action of N- β3/4acetilglucosaminiltransferase (β3/4 GnT) and 
β3/4N-acetilgalactosiltransferase (β3/4 GalT), leading to the formation of the 
oligosaccharide chains type 1 (Galβ1-3GlcNAc-R) and type 2 (Galβ1-4GlcNAc-R) [25, 
32, 42]. These structures may be terminated by antigens Lewis (Le) and ABO blood group 
[43]. More specifically, the Lewis antigens results from modifications in the 
oligosaccharide chains, by addition of fucose and sialic acids. The Le
a
, Le
b 
 and sialyl-Le
a
 
antigens derive from changes in the type 1 chain while, antigens Le
x
, Le
y 
and sialyl-le
y 
antigens
 
result from the addition of fucose residues and sialic acid in the type 2 chain [32]. 
Sialylation of Lewis determinants results from the action of α2-3 sialyltransferases, 
ST3Gal-III and ST3Gal-IV/VI. These enzymes promote the transfer of sialic acids to the 
O-3 position of Gal residues in type 1 and type 2 chains, resulting in the formation of the 
sLe
a
 and sLe
y
 antigens, respectively [32, 40]. 
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Figure 2: Representation of the pathways of biosynthesis of O-glycans of mucins common with the main 
tumor associated antigens highlighted: polypeptide N-acetylgalactosaminyltransferases (ppGalNAc-Ts); 
sialyltransferases ST6GalNAc and ST3/ST6Gal; core 1 β1-3 galactosyltransferase (C1GalT); core 3 β1-3 N-
acetylglucosaminyltransferase (C3GnT); Core 2 β1-6-N acetylglucosaminyltransferase (C2GnT); 
fucosyltransferases (αFuc-Ts), β1-4/3 galactosyltranferases (β4/3Gal-Ts) and β1-3/4 N-
acetylglucosaminyltransferases (β3/4Gn-Ts).(Adapted from [25] ). 
 
2.1. Alterations of O-glycosylation in tumors  
 
The pattern of protein glycosylation is cell and tissue specific [36] and closely 
reflects the physiological status of the cell. Thereby, changes in glycan expression are 
being observed for several pathological conditions and in particular in during malignancy 
[27, 36, 44-48]. The first evidence of this fact resulted from the observation of plant lectins 
binding of tumor cells in animals [49]. In late 1980s, researchers concluded that, many of 
the available tumor specific antibodies showed reactivity against abnormal glycan 
structures [50, 51].  
The most common changes occur in the O-glycosylation of tumor cell-surface and 
secreted glycoproteins; still the functional significance of these alterations is less well 
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understood [52]. These include the expression of abnormal core structures, increased 
synthesis of terminal structures, including Lewis blood group related antigens [53] have 
been reported. However, the majority of the studies consensually report a high expression 
of incomplete O-glycans such as sialyl Tn and other sialylated T-related antigens (Figure 
3) [32].  The over-expression of these simple mucin type O-GalNAc glycans are common 
too many solid tumors, namely breast [45], oesophagus [54], colon [55], stomach [56], 
ovarian [57], bladder [28, 58, 59], among other tumors. Moreover, they have been 
associated with poor prognosis in patients with breast [45], colon and stomach [27] 
carcinoma. In particular, sTn is considered a pancarcinoma antigen, since it was found in 
several epithelial tumors, including colorectal [60], ovarian [61], breast [62], pancreatic 
[63] and gastric carcinomas [64], while absent in the healthy mucosa [65]. 
 
 
 Figure 3: Structures of Thomsen-Friedenreich antigens (Adapted from [32])  
 
 
The expression of T antigens was also found elevated in kidney, prostate, cervix, 
ovary, breast, liver, stomach and colorectal carcinomas [66]. The mono and disialylated 
forms of the T antigens can be found in healthy tissues but are significantly over-expressed 
in several tumors. These include testicular neoplasms [67], bladder tumors [28] and 
pancreatic adenocarcinomas [68]. However, very few studies distinguish the nature of the 
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type of sialylation present. Moreover, S6T has been mostly associated with malignancy in 
vitro [30, 69].  
The majority of these alterations have been correlated with deregulations in the 
expression of glycosyltransferases [39, 70]. Specific changes have been described to occur 
in the initial steps of O-glycosylation. The enzymes responsible for initiating processing 
steps of O-glycans (GalNAc-Ts, and C1GalT C2GnT) are enriched in the cis-Golgi, while 
a later by the action of the sialyltransferases is effected in the trans-Golgi [70]. Recently, a 
new mode of regulation has been evidenced where the activation of protein kinase Src, 
selectively redistributes the enzymes located in the GC to the ER. Src kinase is a known 
tyrosine kinase proto-oncogene that is overexpressed in several human cancers [71]. 
Interestingly, the Src activity is not required for tumor growth, but is required for 
metastasis in several types of tumor [72]. These observations were correlated with the 
ability of citoplasmatic phosphorylation of the proto-oncogene, promoting cell adhesion. 
Recent findings suggest that, the activation of Src, promotes the relocation of GalNAc-T 
for RE resulting in an increase in the initiation locals of O-glycosylation, with of high 
levels of O-glycans short chain to the cell surface. In this context, it should be noted that 
the RE is a higher pH (around 7) for the GC (pH = 6.5) [73], making it possible that the 
catalytic activity and / or substrate preferences for the altered glycosyltransferases can also 
be a result of pH changing [36]. 
Other mechanisms leading to the accumulation of low molecular weight glycans 
include the upregulation/downregulation of glycosyltransferases, in particular 
sialyltransferases [74].  Namely, STn has been connoted with the high expression of 
sialyltransferases ST6GalNAc-I/II, but in particularly ST6GalNAc-I [30]. It has been 
advanced that this enzyme may compete with other glycosyltransferases, such as core 1 β1-
3-Galactosyl-transferase [32] thus leading to a premature stop in O-glycosylation. Other 
mechanisms include the translocation of ST6GalNAC-I to early sub-compartments of the 
Golgi apparatus. The overexpression of STn may also result from a blockage in the 
expression of core 1 and core 3, making the Tn epitope available for sialyltransferases. 
Mutations in Cosmc gene that encodes Cosmc, a molecular chaperone required for the 
activity of core 1 β3-Gal-T has also been related with an enhanced synthesis of STn and Tn 
antigens [65, 75]. The high expression of STn is associated with aggressiveness and 
metastasis potential of the epithelial carcinomas [61] and is an independent indicator of 
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poor prognosis in gastric [76], ovarian [77] and colorectal cancer [60]. Naturally occurring 
antibodies to STn have been detected in gastrointestinal and ovarian cancer patients raising 
the possibility of immune response towards this epitope [78]. The ST has been associated 
in several studies with an increase in the expression of α2-3sialyltansferases, namely 
ST3Gal-I [28, 70]. Another study concerning pancreatic carcinoma has demonstrated that 
ST can result from a down regulation in core 2 β1-6-N-acetylglucosaminyltransferase, 
which is required for elongation of the mucin-type glycans [68]. The over-expression of 
UDP-Galactose transporters was also implicated in induction of expression of T antigen in 
tumor cells [32, 66]. Thus, several factors such as availability and location of the sugar 
donor  and substrates, disruption of secretory organelles (CG and RE) as well as the 
presence of mutations, have been demonstrated to affect the activity and expression of 
glycosyltransfera a consequently the processing of O-glycans [79, 80]. 
 
2.1.1. Biological implication of simple mucin type O-GalNAc antigens 
 
The structural alteration occurring in the O-glycosylation of proteins accompanying 
malignant transformations are reactively well identified. On the other hand, the biological 
alterations resulting from these events are still fairly understood. Yet, some studies have 
demonstrated a direct link between the aggressiveness of the cancer and the density of 
expression of simple mucin type O-GalNAc glycans [81-83]. In particular, in vitro studies 
have shown that the expression of STn contributes to alter cell recognition by the immune 
system [84], affects the adhesive properties of cancer cells, promotes invasion and 
metastasis [56, 64, 85].  Furthermore, STn appears to play a role in avoiding the 
elimination of metastatic cells in the blood stream by the immune system [65, 86]. This 
way, the sialic acids have repeatedly been implicated in the metastatic process. As a result, 
it is being explored as a serum biomarker of poor prognosis in gastric [76, 87], colorectal 
[88] and ovarian cancer carcinomas and in 74 tumor vaccines [77].  
On the other hand, the T antigens are functionally important in cancer progression 
by allowing increased interaction or communication of the tumor cells with endogenous 
proteins. Namely, T antigens can bind circulating proteins, such as galectins, which in turn 
are involved in the regulation of cell progression, adhesion and metastasis [89]. These 
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interactions prevent the recognition of tumor cells by immune cells, thus providing a 
mechanism to escape the immune surveillance [66]. 
 
2.1.2. Alteration in expression of O-glycans in bladder cancer 
 
The altered nature glycosylation of bladder cancer cell-surface and secreted 
glycoproteins has been long demonstrated [90-92]. It comprises aberrant N-glycan 
branching, over-sialylation, loss of ABO blood groups and/or abnormal Lewis (Le) antigen 
patterns [86]. Differentiated Le
y
 expression was identified for CIS and non-CIS [93] while 
the presence of SLe
x
 and/or SLe
a
 has been putatively correlated with invasive and 
metastatic potentials [86, 93]. However very few reports, published more than 20 years 
ago, have addressed the expression of simple mucin type O-GalNAc glycans [28, 41]. 
These studies have demonstrated that T and Tn are over-expressed in bladder 
carcinoma cells compared to normal cells where the expression is practically non-existent 
[27, 28]. In particular, Limas C. et al.,(1991) evaluated by immunohistochemistry the 
expression of the T antigen in biopsies from 56 patients at various stages of the disease. 
This author found that T was characteristic of more advanced stages and was almost absent 
from the healthy urothelium [29]. Also, the studies by Langkilde et al.,(1995) concluded 
that there is a correlation between T-antigen expression and recurrence or progression of 
initially non or superficially invasive human bladder tumors [94].  An additional study by 
Yamada et al.,(1988) [95] has demonstrated that cryptic T antigens (ST comprising S6T, 
S3T and DST) was normally expressed by non-invasive or superficially invasive (Ta or T1) 
papillary tumors. These authors added that ST expression was partially or completely lost 
in tumors that showed malignant progression after frequent recurrences. In line with these 
observations, recently Videira et al.,(2009) [28] demonstrated that ST3Gal-I plays the 
major role in the sialylation of the T antigen in bladder cancer. According to this study, the 
overexpression of ST3Gal-I seems to be part of the initial oncogenic transformation of 
bladder and can be considered when predicting cancer progression and recurrence [28]. At 
this point the expression pattern of STn as well as the individual expression of S3T and 
S6T remains unknown.  
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1. Aim and Scopes 
 
The management of high-risk bladder tumors poses a major challenge due to the high 
volume of recurrences and increased risk of progression to invasion. Currently the most 
efficient therapeutics includes transurothelial resection of the tumor followed by 
immunotherapy with BCG. However, this approach entails health risks and often fails to 
prevent poor outcome. Upon therapeutic failure and/or muscle invasion the patient is faced 
with cystectomy [2]. Hence, bladder cancer represents an opportunity and challenge for 
molecularly-targeted therapy, making of the molecular characterization of the tumors a 
mandatory task. Also, foreseeing those best served by an alternative or even more 
aggressive such as early cystectomy, would avoid disease progression, reduce disease 
burden and decrease health expenses. However, at the moment there are no biomarkers to 
predict BCG therapeutics outcome [20].   
 It is now well established that tumor cells express simple mucin type O-GalNAc 
glycans [27, 28] that contribute to malignancy and constitute a major source of cancer 
biomarkers [25]. Moreover they have been explored in cancer vaccines [78]. Still, little is 
known about the expression of these glycans by bladder tumors. Based on these 
considerations, the first part of the present work aims to characterize the expression of 
these antigens in BC. Considering their association with increase malignant potential [24], 
it is hypothesized high-risk cases may present distinct O-glycan patterns. The second part 
of the work is dedicated to determine the predictive value of altered O-glycosylation 
associated with high-risk tumors in the outcome of immunotherapy with BCG.  
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1. Analytical Approaches  
 
The identification of O-glycosylated epitopes (T, Tn, ST, STn, S6T and S3T) was 
performed in a prospective series of 29 bladder tumor tissues with different histological 
natures (low and high grade NMIBC and MIBC) from patients from the Portuguese 
Oncology Institute of Porto. This was done by immunohistochemistry in formalin fixed 
paraffin embedded (FFPE) using a combination of monoclonal antibodies and enzymatic 
treatments that have been resumed in Table 1. The observed structures where further 
validate by nanoLC-ESI-MS/MS. Briefly, prior to MS analysis, the proteins were extracted 
from the tissue and the O-glycans were isolated by reductive beta elimination followed by 
permethylation. This procedure equalized their chemical properties rending them 
hydrophobic and allowing their detection in positive ion mode [96]. Moreover, it stabilized 
labile residues such as sialic acids [96]. The second part of the work concerned the 
evaluation the O-glycans associated with high-risk tumors, by immunohistochemistry, in a 
retrospective series of 94 NMIBC cases treated with BCG collected by the Pathology and 
Experimental Therapeutics of the Portuguese Institute of Oncology, Porto).  
 
Table 1: Studied antigens and monoclonal antibodies specific. 
 
 
Antigen Antibody Dilution 
T 3C9 1:10 
ST 3C9 after neuraminidase 1:10 
Tn IE3 1:10 
STn TKH2 1:20 
S6T TKH2 after β (1,3) galactosidase 1:10 
S3T 3C9 after α(2-3) Neuraminidase 1:10 
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Abstract 
 
Simple mucin type O-GalNAc glycans are commonly over-expressed in solid 
tumors and have therefore been explored as cancer biomarkers and in therapeutics. Still, 
little is known regarding their expression in bladder tumors. Taking this into consideration, 
the present work was dedicated to characterizing these antigens in 29 bladder tumors with 
different clinicopathological natures, low grade (n=17) and high grade (n=7) NMIBC and 
MIBC (n=5) by immunohistochemistry. The expression of the Tn, STn and T antigens 
were directly evaluated using monoclonal antibodies with 1E3, TKH2 and 3C9, 
respectively. The ST and S3T were determined using 3C9 after treatment with a -
neuraminidase and a -(2-3)-neuraminidase, respectively. S6T was determined using 
TKH2 after treatment with a -(1-3)-galactosidase.  
This study has demonstrated that sialylated species predominate over neutral 
antigens Tn and T. S6T had broader expression (approximately 90% of the tumors) being 
prevalent among high grade cases. The S3T expression was more restricted (48%) being 
that, it was also associated with high grade. The presence of S6T and S3T was confirmed 
by mass spectrometry. To our knowledge, these antigens are being reported in bladder 
tumors for the first time. It was also observed that STn is characteristic of high grade and 
invasive tumors (71 and 80% respectively) that currently constitute the primary concern in 
bladder cancer management. Thus, important information was collected that may guide 
future studies in the understanding of tumor behaviour, definition of high-risk populations 
and therapeutics.  
 
 
 
Keywords: Bladder cancer, O-GalNac glycans, sialylated antigens, 
immunohistochemistry, mass spectrometry.  
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1. Introduction 
Bladder cancer is the fifth most common cancer in Western society and a growing 
concern in developing countries, as a result of demographic expansion and increased of 
life-expectancy [1, 2]. At presentation, most cases are superficial, non-muscle invasive 
bladder cancers (NMIBC), conservatively treated by complete transurethral resection 
(TUR) [3]. However, approximately half are burdened by a high volume of recurrences 
and present an elevated risk of progression to muscle invasive disease correlated with poor 
prognosis. According to the European Organization for Research and Treatment of Cancer 
(EORTC) this group mainly includes high grade papillary tumors and carcinoma in situ 
(CIS), both cases with multifocal lesions [3]. Thus, presently, the degree and stage are the 
most important prognostic factors for the risk of relapse and progression. Yet, due to the 
heterogeneous biological behaviour of tumors and the inter/intra-observer variability the 
accuracy of these models is as high as 70% [4, 5]. It is now consensual that the integration 
of multiple biomarkers can improve the predictive value of this model, making of the 
molecular characterization of bladder tumors a mandatory enterprise.  
Glycosylation is a common post-translational modification of proteins with more 
than 50% of eukaryotic proteins thought to be glycosylated [6]. The pattern of protein 
glycosylation is cell and tissue specific [7] and closely reflects the physiological status of 
the cell. Thereby, changes in glycan expression have been described for several 
pathological conditions and in particular cancer [8]. The altered nature glycosylation of 
bladder cancer cell-surface and secreted glycoproteins has been long demonstrated [9-11]. 
Few reports also refer that some bladder tumors may express the low-molecular weight, 
simple mucin-type O-GalNAc antigens Tn and T antigens and their sialylated counterparts 
STn and ST [12, 13]. These epitopes result from a premature stop in protein O-
glycosylation and have been described to affect the adhesive properties of cancer cells, 
promote their invasive, metastatic and angiogenic potential and alter recognition by 
immune cells [14, 15]. Still, the low number of cases, the high heterogeneity of the 
populations, and the multiplicity of objectives behind the studies presented so far 
prevented the establishment of a pattern of expression for these glycans. Among the most 
studied are the sialylated forms of T antigens, whose over-expression has been found in 
some types of cancers (colon, prostate, cervix, ovary, breast) and correlated with worse 
prognosis [13, 16]. Still, sialylated T antigens have been classically determined based on 
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the reactivity to Peanut Agglutinin (PNA) [17] and/or monoclonal antibodies [18] towards 
the T antigen after the removal of sialic acids with a neuraminidase. The lack of 
discrimination between S3T and S6T led to classify them under the generalist designation 
of cryptic T antigens. Thus, the present work is dedicated to the characterization of simple 
mucin-type O-GalNAc antigens in bladder tumors of different clinicopathological natures.  
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2. Material and Methods 
 
2.1. Patient and sampling 
 
Twenty-nine formalin-fixed, paraffin embedded tissues (FFEP) were prospectively 
collected from 27 male and 2 female patients, mean age of 70 (year range 45–89), who 
underwent bladder surgery in the Portuguese Institute for Oncology of Porto (IPO-Porto, 
Portugal), between July 2011 and May 2012. Based on urothelial carcinoma grading and 
staging criteria of the World Health Organization, three different groups were considered, 
low-grade (n=17) and high grade (n=7) non muscle-invasive papillary bladder cancers 
(NMIBC) and muscle-invasive (n=5) cancers (MIBC). All procedures were performed 
under the approval of institutions Ethics Committee of IPO-Porto and HSJ-Lisbon after 
informed patient’s consent. All clinicopathological information was obtained from 
patient´s clinical records.  
 
2.2. Immunohistochemistry for simple mucin type O-GalNAc 
glycans 
 
Formalin-fixed paraffin embedded (FFPE) urothelium sections were screened for 
the glycans of interest by immunohistochemistry using the avidin/biotin peroxidase 
method. Briefly, 3 m sections were deparaffinised and hydrated with xylene and graded 
ethanol series, and exposed to 3% hydrogen peroxide in methanol for 20 minutes, to reduce 
endogenous peroxidase activity.  
The expression of the Tn, sialyl-Tn and T antigens was then directly evaluated 
using mouse monoclonal antibodies 1E3, TKH2 and 3C9, respectively. The expression of 
cryptic T antigens ST, comprehending ST3, S6T and DST was accessed after treating the 
sections with an non linkage-specific -neuraminidase from Clostridium perfringens 
(Sigma-Aldrich). The S3T antigen was determined using 3C9 after treating the sections 
with an α(2→3)-neuraminidase from Streptococcus pneumonia (Sigma-Aldrich). The S6T 
antigen was determined using TKH2 after treating the sections with a recombinant β-(1-3)-
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Galactosidase from Xanthomonas campestris (R&D systems). Prior to analysis, the 
sections were blocked with normal serum from Vectastain Elite ABC peroxidase kit 
(Vector Lab) for 30 minutes to avoid non-specific staining and then incubated with the 
enzymes, whenever the case, for 2 hours at 37ºC. The sections were then further incubated 
with specific antibodies at 37ºC for 30 min. Afterwards the sections were washed with 
PBS-T and incubated at room temperature for 30 minutes with the diluted biotinylated 
secondary antibody and then with Vectastain Elite ABC reagent (Vector Lab).  After 
washing in PBS-T, the sections were incubated with 3,3-diaminobenzidine 
tetrahydrochloride (ImmPACT™ DAB, Vector Labs) for 5 minutes at room temperature to 
visualize antibody binding sites. Finally, they were counterstained with hematoxylin for 1 
minute. Positive and negative control sections of intestinal metaplasia were tested in 
parallel. The negative control sections were performed by adding BSA (5% in PBS) devoid 
of any immunogen.  
A semi-quantitative approach was established to score the immunohistochemical 
labeling based on the intensity of staining and the percentage of cells that stained 
positively. The sialyl-Tn labeling was be assessed double-blindly by two independent 
observers and validated by an experienced pathologist. Whenever there was a 
disagreement, the slides were reviewed, and consensus was reached. 
 
2.3. Protein extraction from FFPE bladder tumors 
  
The proteins were extracted from FFPE sections (3x10 m) after deparaffinization 
of the tissue using Q-proteome FFPE Tissue Kit (Quiagen). The amount of protein in each 
fraction was determined using the RC-DC kit (BioRad) and the purity of RNA extracts 
determined based on the ration between A280/A260. 
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2.4. Identification of simple mucin type O-GalNAc glycans by mass 
spectrometry  
 
2.4.1. Isolation of O-glycans 
  
Proteins extracted from FFPE tissues were first de-O-glycosylated by reductive -
elimination upon incubation with 50 mM NaOH and 1M NaBH4 at 45ºC for 16 hours.  The 
reaction was stopped with glacial acetic acid until no fizzing was observed and the samples 
were subsequently filtered using 10-kDa molecular weight cutoff (MWCO Millipore). The 
filtrated containing low molecular weight peptides, O-glycans and borate salts was 
recovered and incubated several times with methanol containing 5% (v/v) acetic acid under 
a stream of nitrogen to remove borates as methyl esters.  
  
2.4.2. Stabilization of sialic acids by permethylation  
The O-glycans were then permethylated to stabilize labile sialic acids under ESI 
conditions adopting a modification of the method by Ciucanu and kerek [19]. Briefly, the 
native O-glycans were dissolved in 100 L of DMSO, and powdered NaOH containing 
trace amounts of water was added to the reaction medium. The mixture was sonicated for 
30 min and frozen prior to the addition of 10 L of CH3I and then incubated under mild 
stirring for 1h. The permethylated oligosaccharide were recovered from the reaction 
mixture by extraction with dicloromethane and extensively washed with acidified water 
(pH 2.0) to avoid base-induced hydrolysis of permethylated sialic acids. The samples were 
then de-salted using Dowex ion-exchange resin (Dowex 50W-X8) and dried.  
 
2.4.3. Nano-HPLC- ESI-MS/MS 
The permethylated samples were redissolved in 20% acetonitrile (ACN) aqueous 
solution containing 0.1% formic acid (phase A). Analysis of the samples was carried out 
by an Ultimate 3000 at a constant flow rate of 300 nL/min (Dionex) with a linear gradient 
of 5 to 50% B (95% ACN aqueous solution containing 0.1%formic acid) in 40 min using a 
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Pepmap100 (C18; 3 μm particle size, 0.75 μm internal diameter, 15 cm in length) 
connected to an LXQ-MS (Thermo) interfaced with an online nano-electrospray ion 
source. The electrospray voltage was used at 2.0 kV. The MS was operated in the data-
dependent mode, selecting the 4 most intense parent ions for collision-induced dissociation 
in the LXQ trap per full MS scan. Normalized collision energy was 35.0%. Dynamic 
exclusion was set to initiate a 60 s duration for ions analyzed twice within a 15 s interval. 
The scan range was set from m/z 200 to 2000. Peak assignments in MS and MS/MS spectra 
were performed using the GlycoWorkBench platform [20]. 
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3. Results and Discussion 
 
The change in the O-glycosylation pattern of bladder tumors has been long 
demonstrated [12, 17, 21]. However, only one study by Videira et al., (2009) [13] as 
addressed this matter in the last twenty years. Moreover, there is little information 
regarding the expression pattern of simple mucin type O-GalNAc glycans in bladder 
cancer and their correlation with current clinicopathological classifications as defined by 
WHO guidelines. Adding to this, no attempts have been made to differentiate the sialylated 
forms of the T antigen. As such, this work is dedicated to the identification of novel O-
GalNAc antigens and characterization of their expression pattern in bladder cancer.  
Herein, 29 tissues FFPE bladder sections comprehending low (n=17) and high 
grade (n=7) NMIBC and MIBC (n=5) were screened by immunohistochemistry for simple 
mucin type O-glycans, using specific monoclonal antibodies. These included the Tn, STn, 
T antigens and its monosialylated forms S3T and S6T, which is regarded as a rare O-
glycosylation, until now, mostly observed in vitro [22, 23]. The overall expression of 
sialylated T antigens (ST; cryptic T antigen), comprising S3T, S6T and DST was also 
determined. Noteworthy, S3T and S6T are being evaluated for the first time in bladder 
tumors. Simple mucin type O-GalNAc antigens can be found in the plasmatic membrane 
and, to some extent in the cytoplasm of tumor cells. Figure 1 is representative of some 
examples of the fact in question. These observations are consistent with previous reports 
associating these antigens with membrane glycoproteins and proteins in secretion granules 
within the cell [24].  
 
3.1. Expression of Tn, T and ST antigens 
 
In addition, Table 1 shows that the Tn and T exhibit the lowest levels of expression 
(<30% of the total cases).  However, while the Tn antigen is characteristic of high grade 
tumors (57%) and absent in MIBC, the T antigen is more expressed among MIBC cases 
(40%). It was also observed that the T antigen (24% in low grade) predominates over Tn 
(12% in low grade) in low grade papillary tumors. This suggests that core 1 synthase (T-
synthase) expression may be reduced in high grade tumors.  Conversely, ST antigen was 
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detected in all tumors, highlighting a predominance of sialylated structures over neutral 
forms. Thus, an over-expression and/or increased activity of sialyltransferases may be 
expected. In line with these observations, it has been described that several 
sialyltransferases known to promote the sialylation of the T antigens are overexpressed in 
solid tumors [12, 13, 16]. This was also the case of bladder cancer [13]. Table 1 further 
highlight that simple mucin-type O-GalNAc glycans are fairly observed within the tumors, 
in the majority of the cases not exceeding 15% of the section. Additional studies should be 
carried out in order to identify the influence of the clones exhibiting altered O-glycans in 
tumor biology. 
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Table 1:  Expression of simple mucin type O-GalNAC glycans in BC of different clinicopathological natures 
determined by immunohistochemistry. 
                  Tn STn T ST S6T S3T 
 No. of cases 
  
 
Low Grade 
       
17 
      
-  15 (88%) 13 (76%) 13 (76%) 0 (0%) 2 (12%) 10 (59%) 
+      2 (12%) 4 (24%) 4 (24%)    5 (29 %) 11(65%) 6 (35%) 
++       9 (53%)  4 (24%) 1 (6%) 
+++        1 (6%)   
++++       2 (12%)   
Positive 
Cases (n.%) 
  
2 (12%) 
 
4 (24%) 
 
4 (24%) 
 
17 (100%) 
 
15 (89%) 
 
7 (41%) 
  
  
High Grade 7       
-  3 (43%) 2 (29%) 5 (71 %) 0 (0%) 0 (0%) 2 (29%) 
+  4 (57%) 4 (57%) 2 (29 %) 2 (29%) 3 (43%) 4 (57%) 
++   1 (14%)   3 (43%) 1 (14%) 
+++     1 (14%) 1 (14%)  
++++     4 (57%)   
Positive  
Cases (n.%) 
  
4 (57%) 
 
5 (71%) 
 
2 (29%) 
 
7 (100%) 
  
7 (100%) 
 
5 (71%) 
  
  
Invasive 5       
-  5 (100%) 1 (20%) 3 (60%) 0 (0%) 2 (40%) 3 (60%) 
+   4 (80%) 1 (20%)   2 (40%) 2 (40%) 1 (20%) 
++    1 (20%)  1 (20%) 1 (20%) 
+++        3 (60%)   
++++        
Positive  
Cases (n.%) 
  
0 % 
 
4 (80%) 
 
2 (40%) 
 
5 (100%) 
 
3 (60 %) 
 
2 (40%) 
        
        
Total positive 
cases 
29  
6 (21%) 
 
13 (45%) 
 
8 (28%) 
 
29 (100%) 
 
26 (86%) 
 
14 (48%) 
(NMIBC+MIBC)       
 
 
  
Score of extension Staining 
Negative - 
>0-15% + 
16-30% ++ 
31-45% +++ 
≥46% ++++ 
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Figure 1: Illustrative representation of immunohistochemistry of (ST, S3T and S6T) for each of the types of 
lesions presents in this study (Low-Grade, High-Grade and Invader). 
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3.2. Expression of S6T and S3T 
 
The enzymatic treatment of the tissues with a -(1-3)-galactosidase allowed 
positive staining in, up until now and non-reactive sections for anti-STn monoclonal 
antibody TKH2 (Figure 2 A/C). This removed O-3 linked Gal residues from ST exposing a 
STn antigen and demonstrating, for the first time, that bladder tumors express S6T. This 
antigen was found in 86% of the tumors, predominantly among high grade NMBIC 
(100%). Approximately 89 % and 60% of low grade and MIBC correspondently, were also 
positive. S6T was further evaluated in FFPE healthy urothelium from six necropsied male 
individuals, available in the laboratory at the time of the experience. The absence of 
antigens in these tissues allowed concluding that S6T is a bladder tumor specific 
glycosylation. It further suggests that ST6GalNAC-I and/or II or ST6GalNAC-IV known 
to be involved in the O-6 sialylation of Tn antigens, may be over-expressed in bladder 
tumors. However, other factors such a reduced expression of the glycosyltransferases 
responsible by chain elongation and alterations in the secretory pathways may also 
contribute for it. Given the clinical relevance of this observation further studies should be 
conducted to evaluate its biomarker value. Taking into account the pancarcinoma nature of 
simple mucin-type O-glycans this strategy can be applied to screen other solid tumors for 
this particular glycan.   
On the other hand, incubation with a -neuraminase specific for O-3 linked 
residues allowed positive staining in, up until now, non-reactive sections for anti-T 
mononclonal antibody 3C9 (Figure 2 B/D). This enzyme removed O-3 linked Neu5Ac 
residues from S3T, thus exposing a T antigen. According to a previous study by Videira et 
al.,(2009) [13], bladder tumors over-express ST3Gal-I, which is the sialyltransferase 
responsible by the O-3 sialylation of  the T antigen. These results now provide the 
structural confirmation that S3T is present in bladder tumors. However, S3T has a more 
restricted pattern of expression than S6T, as it was only found in 48% of the cases. It was 
more pronounced among high grade tumors (71% of the cases) when compared to low 
grade and MIBC (41% and 40 % respectively). The lack of healthy urothelium at the time 
of the experiment did not allow determining whether this antigen may be present in non-
pathological conditions. It was also observed that all S3T positive cases were also S6T 
positive, which demonstrates that both sialylated forms of the T antigen can coexist within 
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the same tumor. However, 34% of the cases (n=10), predominantly low grade (70% low 
grade, 10% high grade, 20%  MIBC) were S6T positive but did not express S3T. This 
suggests either an over-expression of O-6 sialyltransferases acting on the T antigen 
(ST6GalNAC-I/II/IV) or the lower expression of O-3 linked sialyltransferases (ST3Gal-
I/II/V). Competitive factors between both enzymes as well as environmental changes may 
also play an important role in the predominance of S6T over S3T.  
 
Figure 2: Positive staining of S6T (A) and S3T (B) and non-reactive sections of anti-STn (C) and anti-T (D). 
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Given the novelty of these observations, S6T and S3T were also accessed by mass 
spectrometry. Proteins were first isolated from FFPE over-expressing these antigens, 
chemically de-O-glycosylated as described in the Materials and Methods section and 
analyzed by nano-LC-ESI-MS/MS. However, our preliminary studies using SLe
x
, that 
exhibits an O-3 linked Neu5Ac residue, have demonstrated that sialic acids can be lost 
under soft ionization methods such as electrospray. To overcome this limitation by 
reducing the lability of acidic moieties, the glycans were permethylated prior to analysis. 
This also promoted and equalization of their chemical properties allowing the detection of 
both neutral and acidic species in positive ion mode. This approach allowed the 
identification of an ion at m/z 437.25 corresponding to [ST+2H]
2+
. This assignment was 
confirmed based on the characteristic product ion spectra presented in Figure 3. This 
MS/MS spectra predominantly exhibited ions resulting from combination of X-type cross-
ring fragmentations with one or several B-, C-, Y- and Z-type fragmentations 
(nomenclature fragmentation according to Domon and Castello (1988) [25] that have been 
summarized in Table 2 and identified in Figure 3.  Combined cross-ring and glycosidic 
bond cleavages occurring at both the reduced and non-reduced terminal ends are 
characteristic of permethylated glycans under tandem conditions [26]. Among these, are 
the ions at m/z 291.15 and 309.03 corresponding to a sialic acid residue linked to a Gal 
residue (Figure 3; Table 2) characteristic of S3T. On the other hand, the product ions at m/z 
364.27 and 406.34 resulting from sialic acids linked to a GalNAc residue are characteristic 
of S6T. Other, less intense ions characteristic of both isomers are summarized in Table 2. 
These reporter ions demonstrate the coexistence of the two isomeric structures in samples 
over-expressing both S3T and S6T, thus validating immunohistochemistry observations.  
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Figure 3: A) ESI-MS spectrum showing the ion at m/z 437,25 assigned to [ST+2H+]
2+
. B) Partial overview 
of the product ion spectra of the ion at m/z 437.25 assigned to [ST+2H]
2+
 . The more intense reporter ions for 
S6T at m/z 364.27 and 406.34 and the reporter ions for S3T at m/z 291.15 and 309.3 have been highlighted. 
The fragmentations are presented according to the nomenclature introduced by Domon and Costello [37]. “*” 
signals resulting from the combination of cross-ring and glycosidic bound fragmentations occurring at both 
the reducing and non-reducing ends. (  - Gal;  - GalNAc; - Neu5Ac).  
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Table 2: Resume of the less intense ions observed in the spectrum of Figure3 that are reporters of S3T and 
S6T. (  - Gal;  - GalNAc; - Neu5Ac).  
ion (m/z) Charge Ion type Assigned structure O-glycan 
     
167.10 2H B
0,3
X2  
 
S3T 
228.19 2H C
1,4
X2 
 
S3T 
244.08 H ZZ 
 
S6T 
261.19 2H
+
 
1,5
X1β 
0,4
X1α 
 
S6T 
418.58 H B
0,4
X2 
 
S3T 
 
 
3.3. Expression of STn 
  
Despite its pancarcinoma nature and association with malignancy, the expression of 
STn in bladder cancer remains uncharacterized. This study is now showing that STn is 
mostly expressed in high grade and invasive tumors (71 and 80% respectively), whereas 
only 24% of low grade cases were positive. The majority of the positive cases presented a 
low extension of expression (<15%), of focal and polydisperse nature throughout the 
tumor.  STn was mostly found in cells of the basal layer (Figure 4 A); yet in tumor areas 
presenting extensive staining (>50%) (Figure 4 B), it could also be detectable in papillary 
urothelium and invasive fronts (Figure 4 C). Moreover, we have found that whenever 
present in the tumor, STn was also detectable in the adjacent but not in the distal mucosa. 
Hence, cells neighbouring the tumor are thought to carry significant alterations that result 
in the expression of this antigen. Further studies should be conducted to access the 
Chapter IV 
 
 
 
50 
biomarker value of STn in the delimitation of tumor boundaries. Adding to these 
observations, STn was not found in healthy urothelium from necropsied male individuals 
(n=6), thus demonstrating its tumor-specific nature. These results further suggest that 
ST6GalNAC-I or II may be over-expressed in high grade and MIBC.  
 
 
 
Figura 4: Representation of the STn positive staining. (A: Basal layer staining; B: Extensive STn staining (> 
50%); C: Papillary and Invasive fronts staining) 
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4. Conclusions 
 
The evaluation of the expression of O-glycosylated epitopes in 29 neoplastic lesions of 
the bladder, performed by immunohistochemistry, revealed a high incidence of expression 
of sialylated antigens in bladder tumors, irrespectively of their classification. Moreover, 
two novel sialylated species were detected in these tumors, S6T and S3T, however with 
distinct patterns of positivity. S6T showed broader expression (~90% of the tumors) and 
was particularly prevalent among high grade cases. Conversely, S3T expression was more 
restricted (48% of the tumors) being that, it was also associated with high-grade tumors. 
Furthermore, it was concluded that S6T prevailed over S3T, particularly among low grade 
tumors and that S6T was a tumor-specific type of glycosylation. It was also observed that 
the STn antigen expression was almost restricted to more advanced bladder tumors, 
namely high grade and MIBC. This observation is of particular interest since high-grade 
tumors entails an elevated risk of recurrence and progression to muscle invasive disease. 
The identification of high-grade associated biomarker may aid tumor classification, 
provide therapeutic guidance and novel targets for immunotherapy approaches.  
Having established a pattern of expression for simple mucin type O-GalNAc 
glycans in bladder cancer further studies should be conducted to access the clinical value 
of these observations.   
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Abstract 
  
The most effective treatment for bladder cancer patients exhibiting a high-risk of 
recurrence/progression is transurothelial resection followed by immunotherapy with 
Bacillus Calmette-Guérin (BCG). Even though this therapeutics successfully delays 
recurrence, approximately 15% of the initial responders end up progressing to muscle 
invasive disease. Foreseeing those best served by an alternative or even more aggressive 
such as early cystectomy, would avoid disease progression, reduce disease burden and 
decrease health expenses. However, at the moment there are no biomarkers to predict BCG 
therapeutics outcome.  
In chapter IV it was demonstrated that that high-grade tumors, constituting the 
majority of the cases indicated for BCG immunotherapy, abnormally express the 
carbohydrate antigen STn. Another study has shown that the expression of STn by bladder 
cancer cell lines resulted in higher adhesion and internalization of the bacillus. Since these 
events that are associated with an increased probability of response, it is hypothesized that 
glycosylation may dictate the success of therapeutics.  Thus, this study was dedicated to 
determining the predictive value of STn in BCG immunotherapy outcome. STn was 
evaluated by immunohistochemistry in a retrospective series of 94 high-risk tumors. This 
showed that positivity for this antigen was associated with a better response to treatment 
(p=0.024). Moreover it highlighted a trend towards an increased survival. The 
incorporation of the S6T antigen, which has a STn domain, into this model increased the 
overall response (p=0.001) and recurrence free survival (p=0.001). Further studies should 
be conducted to fully clarify the implications of these observations in the management of 
bladder tumors. 
 
 
 
Key words: Non-muscle-invasive bladder cancer, bacillus Calmette-Guérin, STn, S6T, 
high-risk bladder tumors. 
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1. Introduction 
To reduce the risk of relapse in high-risk patients, comprehending high-grade 
papillary tumors but also carcinoma in situ, and multifocal and recurrent lesions, are 
submitted to intravesical instillations with Bacillus Calmette-Guérin (BCG) after 
transurothelial resection of the tumor [1, 2]. Although the management of these patients 
has significantly improved, BCG treatment one third either do not respond or show 
intolerance to BCG, 70% of the responders relapse and approximately 15% progress to 
muscle invasive tumors [3, 4]. Upon therapeutic failure and/or muscle invasion the patient 
is faced with cystectomy [5]. Foreseeing those best served by an alternative treatment or 
early cystectomy, would avoid progression, reduce disease charge and decrease health 
expenses. However, at present, the risk of relapse and progression is based exclusively 
with several clinical and histopathological factors (number and size of tumors, number of 
previous relapses, local staging (T) and degree of differentiation) [6, 7]. So, despite some 
promising targets, there are no established biomarkers to determine the success of BCG 
immunotherapeutics [8,13]. 
The success of BCG immunotherapy resides mostly on the capability of the bacillus 
to recognize and efficiently bind to tumor cells. The bacillus is then internalized triggering 
tumour cell apoptosis and host adaptive immune responses [4]. Several lectins able to bind 
human cell-membrane glycans have been identified in Mycobacterium spp., including 
BCG [1], demonstrating that glycosylation acts as mediator of adhesion. In agreement with 
these observations, it was also noted that BCG has a higher rate of adherence and 
internalization to cells expressing STn [9]. Moreover, in chapter IV it was demonstrated 
that high-grade tumors, entailing a high-risk of recurrence with progression, abnormally 
express the carbohydrate antigen STn. This suggests that tumor-specific glycosylation 
could dictate the course of BCG therapeutics. Thus, the present work is dedicated to 
evaluating the role of STn as response predictor to BCG immunotherapy in high-risk 
tumors.  
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2. Material and Methods 
 
2.1. Population 
 
In this study was used a retrospective series of 94 cases with high risk NMIBC. The 
patients were submitted to therapy with BCG on the Portuguese Oncology Institute of 
Porto, between 1998 and 2006. All patients had received intravesical instillation of BCG 
for 6 consecutive weeks, starting 2-3 weeks after surgery (iBCG) and 56.4% were 
submitted to mBCG schedule (iBCG + maintenance protocol  with instillations every 2 or 
3 months during 2 years).  
The male:female sex ratio was of 78:16. The patients were followed every 3 months 
for the first year, every 6 months for the second year and every 12 months thereafter by 
cystoscopy and urine cytology. The tumor recurrence was defined as the appearance of a 
newly found bladder tumor after the treatment, with at least one tumor-free cystoscopy 
between. So, the non-responders were defined as patients submitted to BCG treatment with 
tumor recurrence. 
Finally, recurrence-free survival (RFS) was defined as the period between the 
beginning of BCG treatment until the date of the most recent cystoscopy or recurrence 
date. All clinical and pathological information was obtained from medical records being 
that the institutional ethics committee approved the study. 
 
2.2. Evaluation of STn and S6T by immunohistochemistry 
  
STn was evaluated by immunohistochemistry in formalin fixed paraffin embedded 
tissues using monoclonal antibody TKH2 as described in chapter IV. S6T was also 
evaluated in tumors showing negative staining for TKH2.  
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2.3. Statistical analysis 
The statistical analysis of data was performed using the computer software package 
Statistical for Social Sciences, SPSS for Windows (version 15.0). Chi-square analysis was 
used to compare categorical variables. Logistic regression was used to predict the outcome 
of BCG immunotherapy based on STn and S6T expression and to adjusted variables that 
could affect the outcome. The odds ratio (OR) and its 95% confidence interval (CI) were 
calculated as a measurement of the association between the expression of O-glycosylated 
structures and recurrence. Further, multiple Cox regression analysis was used to assess the 
effect of individual epitopes on the time to recurrence in BCG-treated patients and to 
adjusted variables that could affect the outcome. 
  
Chapter V 
 
 
 
62 
3. Results and Discussion 
 
The first part of this study was dedicated to determining the influence of 
several clinicopathological features (stage, grade, size, number of tumors, presence of 
CIS, recurrence status), treatment scheme (iBCG, mBCG) and other variables (sex) in 
BCG treatment outcome (responders vs. non-responders) (Table 1). Using a Using 
Chi-square analysis, the only variable correlating with recurrence is the treatment 
scheme (iBCG and mBCG). It was observed that the mBCG scheme (iBCG + 
maintenance protocol with instillations every 2 or 3 months during 2 or 3 years), was 
more effective (Table 1). These results are in agreement with previous studies that 
states that maintenance BCG is required in order to achieve the best therapeutic results 
[10]. Thus, subsequent studies addressing the estimation of STn expression in the 
outcome have been carried out taking in consideration this effect. 
 
Table 1: Relation between patients, clinical and tumor characteristics and BCG treatment outcome. 
 
Variables Total Responders Non-Responders p 
 n (%) n (%) n (%)  
Sex     
Male 78 (83.0%) 47 (60.0%) 31 (40.0%) 0.585 
Female 16 (17.0%) 11 (68.8%) 15 (31.2%)  
Stage     
Ta 40 (42.6%) 23 (57.5%) 17 (42.5%) 0.524 
T1 54 (57.4%) 35 (64.8%) 19 (35.2%)  
Grade     
Low 21 (22.3%) 13 (61.9%) 8 (38.1%) 1 
High 73 (77.7%) 45 (61.6%) 28 (38.4%)  
Size (cm)     
<3 62 (66.0%) 38 (61.3%) 24 (38.7%) 0.823 
≥3 31(34.0%) 20 (64.5%) 11 (35.5%)  
Tumor number     
Unifocal 51 (54.3%) 28 (55.0%) 23 (45.0%) 0.201 
Multifocal 43 (45.7%) 30 (70.0%) 13 (30.0%)  
CIS     
No 88 (93.6%) 54 (61.4%) 34 (38.6%) 1 
Yes 6 (6.4%) 4 (67%) 2 (32.3%)  
Recurrence Status     
Primary 48 (51.0%) 31 (64.6%) 17 (35.4%) 0,672 
    Recurrent 46 (49%) 27 (58.7%) 19 (41.3%)  
BCG schedule     
iBCG 41 (43.6%) 20 (48.8%) 21 (51.2%) 0.032 
mBCG 53 (56.4%) 38 (71.7%) 15 (28.3%)  
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The Table 2 shows the correlation between the expressions of STn with the 
response to treatment. In this context, 69.4% of cases that responded to treatment with 
BCG expressed STn. With respect to non-responders, the expression of STn was seen in 
30.6% of cases. Thus, the frequency of STn expression is higher in patients that 
responded to BCG, when compared with non-responders group (p = 0.024). Moreover, 
the risk of developing disease was approximately 65% lower in patients expressing STn 
(OR = 0.346).  
However, taking into account the existence of a high percentage of STn negative 
cases was incorporated into the study, the evaluation of the expression of a sialylated 
structure very similar to the STn. In an attempt to improve this predictive model S6T, 
which may be considered an STn-like antigen, has been evaluated in STn negative 
cases. This permitted to improve both the correlation with response (p = 0.001) and 
lowered the risk of developing disease (OR = 0.170). Such, occurs due to a 
reclassification of STn negative cases responding to BCG to (STn/S6T) positive (Figure 
1).  
 
 
Table 2: Distribution expression of STn and S6T and risk of recurrence after BCG therapy. 
* 
logistic regression  
a
 adjusted for treatment sheme (iBCG/mBCG) 
  
 BCG response    
 Responders Non-Responders OR
a 
95%CI P* 
STn      
      
Negative  15 (46.9%) 17 (53.1%) 1,0 Referent  
Positive  43 (69.4%) 19 (30.6%) 0,346 0,132-0,871 0.024 
      
S6T+STn      
      
Negative  8 (33.3%) 16 (66.7%) 1,0 Referent  
Positive  50 (71.4%) 20 (28.6%) 0,170 0,059-0,489 0.001 
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                         S6T+                           STn- 
 
Figure 1: STn negative and S6T positive case that responded to BCG immunotherapy.  
  
Finally, the Cox regression analysis adjusted to treatment scheme was performed to 
assess the individual effect of STn and STn+S6T on the time to recurrence in BCG-treated 
patients. Table 3 shows that patients with STn positive tumors have a trend to a lower risk 
of early recurrence after BCG treatment (HR=0,551; 95%CI: [0.284-1.070]). Likewise, it 
was observed that the cases involving positive STn+S6T show a statically significant lower 
risk of early relapse after the application of therapy in question (HR = 0.300, 95% CI 
[0.151 to 0.596]). This reinforces the idea that the expression of STn-like O-glycosylated 
structures (STn and S6T) contribute to a decreased risk of developing the disease in 
question after treatment with BCG. So, the immunotherapy with this bacillus may be 
effective in these cases. These observations reinforce previous studies suggesting an active 
role of STn in BCG immunotherapy by promoting adhesion an internalization of the 
bacillus. Whether the described association results from a direct recognition and binding of 
the bacillus to tumor cells remains unknown. The abnormal nature of STn and STn-like 
glycans may also play a determinant role in a better response to BCG. These glycans have 
been proven immunogenic as demonstrated by their exploitation in vaccine formulations 
[11]. Yet, the immunosuppressive environment of tumors often prevents the development 
of an effective response [12]. However, several reports have demonstrated that the use of 
immunological boosters may overcome this limitation [12]. It may be the case that BCG is 
acting in the same way, thus promoting the elimination of tumor cells expressing altered 
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glycosylations. Further studies should be conducted to access this matter and may render 
important clues about novel immunotherapeutics against bladder cancer using altered 
glycosylation. 
 
Table 3: Multivariated analysis and risk estimation of sTn and S6T influence 
 
 
 
 
 
 
  
 HR 95%CI P 
STn    
Negative 1.0 Referent  
Positive 0,551
 
0,284-1.070 0.078 
    
S6T+STn    
Negative 1.0 Referent  
Positive 0,300
 
0,151-0.596 0.001 
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4. Conclusion 
 
 One of the most critical aspects in managing bladder cancer in patients with a high-
risk of recurrence/progression is to predict the outcome of adjuvant immunotherapy with 
BCG. Moreover, at the moment there are no biomarkers to anticipate this event.  
 Herein it has been demonstrated that the expression of abnormal O-glycans STn 
and S6T correlated with a better response to this treatment. It is expected that these glycans 
in association with other BCG-response associated molecules already identified [8] may 
allow the establishment of a predictive panel that can guide therapeutic decision. 
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1. General Conclusions 
The first part of this work has been dedicated to defining a pattern of expression for 
simple mucin type O-GalNAc glycans in bladder cancer. In agreement with observations 
for other solid tumors, it was concluded that sialylated forms predominate over neutral 
glycans. Also, two novel sialylated species were detected in these tumors, S6T and S3T. 
S6T prevailed over S3T, particularly among low grade tumors and was found to be a 
tumor-specific type of glycosylation. Conversely, S3T was more frequently expressed in 
high-grade tumors. Contrasting with the monosialylated forms of the T antigen, STn 
expression was almost restricted to more advanced bladder tumors, namely high grade and 
MIBC. This observation is of particular interest since high-grade tumors entails an elevated 
risk of recurrence and progression to muscle invasive disease. The tumor-specific nature of 
these antigens and their differentiated pattern of expression make believe they could be 
valuable biomarkers and constitute targets for novel therapeutics.  
Finally, it was evidenced that the expression of abnormal O-glycans STn and S6T is 
correlated with a better response to treatment with BCG. It is expected that these glycans in 
association with other BCG-response associated molecules already identified may allow 
the establishment of a predictive panel that can guide therapeutic decision.  
 
  
 
